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Abstract
Background: The effect of adjuvant radiotherapy on the survival outcomes of patients with mucinous rectal cancer
remains unclear. This study evaluated the 5-year cause specific survival (CSS) of patients with mucinous rectal
cancer after surgery to determine whether adjuvant radiotherapy conferred a survival benefit.
Methods: An analysis of the Surveillance, Epidemiology, and End Results (SEER)-registered database was conducted
of patients presenting with mucinous rectal cancer between 2004 and 2011. The primary endpoint was 5-year CSS;
univariate and multivariate analyses were performed using Cox proportional hazards regression models.
Results: A total of 574 patients were included for analysis with 248 patients in postoperative radiotherapy group
and 326 patients in surgery alone group. Preliminary analysis demonstrated that adjuvant radiotherapy was not
associated with CSS (χ2 = 0.560, P = 0.454). Subgroup analysis indicated that postoperative radiotherapy group had
survival advantage in stage II rectal cancer (93.3% vs. 76.6%, χ2 = 4.654, P = 0.031), but not in stage III rectal cancer
(67.5% vs. 64.7%, χ2 = 0.186, P = 0.666). Multivariate analysis demonstrated that postoperative radiotherapy group
had a reduced risk of death on survival (HR 0.346; 95%CI 0.129-0.927, P = 0.035)
Conclusion: Postoperative radiotherapy is an independent factor for improvement in CSS in patients with stage II
rectal mucinous adenocarcinoma, and it should be routinely recommended in these patients. But for stage III
patients, considering the losing of CSS advantage and potential radiotherapy toxicity, postoperative radiotherapy
should be recommended with great caution.
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Background
Colorectal cancer is the third most commonly diagnosed
cancer and the third leading cause of cancer death in
men and women combined in the US [1]. Mucinous
adenocarcinoma (MC) is a histological subtype of colo-
rectal cancer, representing approximately 5-15% of pri-
mary colorectal cancers [2]. In the World Health
Organization (WHO) classification, MC is defined as a
large amount of extracellular mucin which is produced
by secretion from acini and a mucinous layer covering
more than 50% of the tumor [3]. MC has a distinct
clinicopathological entity with an aberrant molecular
background, and it has been reported uniformly associ-
ated with younger patient populations, a later stage of
presentation, and worse outcomes compared to non-
MC [4, 5]. Several studies have reported a poor re-
sponse of rectal MC to neoadjuvant chemoradiother-
apy (NCRT) in terms of downstaging and tumor
regression grade [2, 6], while others found a similar
survival benefit for MC and non-MC [3].
Although NCRT is the current standard of care for
patients with locally advanced rectal cancer, a substantial
number of locally advanced rectal cancers have not
received NCRT due to understage limited by preopera-
tive evaluation. Data from pooled analyses, as well as
from recent smaller studies revealed that the sensitivity
of endorectal ultrasound (ERUS) in detecting lymph
node metastasis ranges from 50 to 83%, comparable with
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that of magnetic resonance imaging (MRI) (sensitivity,
45-79%) [7–9]. Adjuvant radiation therapy is recom-
mended for patients with T3, T4, or N+ rectal cancer to
decrease the risk of local failure [10], which is reported
that about 37% lower in those who had postoperative
treatment than those who had surgery alone [11].
Although histopathological type is an important factor
predicting tumor response to NCRT [12], the value of
adjuvant radiotherapy in MC has not been investigated.
Thus, we conducted this study to investigate the prognos-
tic importance of adjuvant radiotherapy in rectal MC.
Methods
Patient population
The ideal way to investigate the prognostic factors of a
rare disease such as rectal MC is to perform a large
population-based study. In this study, we used data from
the Surveillance, Epidemiology, and End Results (SEER)-
registered database of individuals diagnosed between
2004 and 2011 to explore in detail what aspects of post-
operative adjuvant radiotherapy affects MC survival.
The SEER Program of the National Cancer Institute
(NCI) is an authoritative source of information on can-
cer incidence and survival in the United States. SEER
currently collects and publishes cancer incidence and
survival data from population-based cancer registries
covering 28 percent of the US population [13, 14]. The
National Cancer Institute’s SEER*Stat software (Version
8.1.5) was used to access the database. The inclusion
criteria were as following :(1) patients were diagnosed
from 2004 to 2011; (2) the site code represented Rectum
(C20.9) according to Third Edition of International
Classification of Diseases for Oncology (ICD-O-3); (3)
histology code denoted MC (8480/3); (4) patients were
with no distant metastasis(M0); (5) patients had under-
gone primary tumor resection; (6) patients received
radiotherapy after surgery or surgery alone; (7) patients
were at stage II and III; (8) age of patients was limited to
above 18 years old; (9) information on cancer-specific
survival (CSS) and survival months was available.
Statistical analyses
Patients’ demographic and clinicopathological variables,
including age, sex, race, tumor grade, tumor size, T or N
stage, tumor metastatic status, treatment type, reginal
lymph node retrieval, et al., were retrieved from the
SEER database. The primary endpoint in this study was
rectal cancer CSS, defined as the period from diagnosis
to death due to rectal cancer. Data of patients who died
from other causes or who were alive on the date of their
last follow-up was censored.
A comparison of the categorical variables between
patients with or without postoperative radiotherapy was
conducted using Pearson’s χ2 test. The Kaplan-Meier
method was used to calculate the actual survival rate
and to plot survival curves, followed by the log-rank test
for clinical and histological variables. The Cox propor-
tional hazard regression model was used to identify the
variables that could independently influence survival in
MC. hazard ratios (HRs) and 95% confidence interval (CI)
were calculated, with an HR of <1.0 indicating survival
benefit. All statistical analyses were performed using SPSS
ver.19.0 (SPSS Inc., Chicago, IL), and a value of P <0.05 in-
dicated statistical significance.
Results
SEER database patient characteristics
In our 8-year study period, a total of 574 eligible MC
patients were enrolled in the current study with a majority
of patients being White in race. Figure 1 depicts the flow
chart of the study. There were 248 patients in adjuvant
radiotherapy group and 326 patients in surgery alone
group. The median follow up time was 36 months (0-95
months). The median age at diagnosis was 67 years (range,
25-95 years). Patients with postoperative radiotherapy had
a higher rate of young patients, a higher proportion of
stage III disease, and relative lower ratio of patients with
tumor size less than 5 cm, which reached the level of sig-
nificance (P <0.05). Patient demographics and baseline
characteristics are listed in Table 1.
Survival impact of postoperative radiotherapy in SEER
database
One hundred and eight patients died of rectal cancer at
last follow up. The 5-year CSSs of patients in postopera-
tive radiotherapy group and surgery alone group were
74.8 and 70.5%, respectively, of which the difference was
not statistically significant (χ2 = 0.560, P = 0.454) (Fig. 2).
Subgroup analysis indicated that postoperative radiother-
apy had survival advantage in stage II rectal MC (93.3%
vs. 76.6%, χ2 = 4.654, P = 0.031), but not in stage III rectal
MC (67.5% vs. 64.7%, χ2 = 0.186, P = 0.666) (Fig. 3a and b).
The adjuvant radiotherapy (P = 0.039), tumor size (P =
0.009), and T stage (P = 0.040) were significant risk factors
for poor survival according to univariate analysis (Table 2).
A reduced model was used in the multivariate Cox analysis,
which means only variables that were significantly corre-
lated with prognosis in univariate Cox proportion HR ana-
lysis were included in the next step. Multivariate analysis
demonstrated that tumor size, T stage and adjuvant radio-
therapy were independent predictors of CSS and postopera-
tive radiotherapy were found to have a reduced risk of
death on survival (HR 0.346; 95% CI 0.129-0.927; surgery
alone as reference) (Table 2).
Discussion
In the 1990s, a number of clinical trials found signifi-
cantly improved rates of local recurrence, cancer-related
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deaths, and overall survival with adjuvant radiotherapy
compared to surgery alone [15–17]. Since then, radio-
therapy has become the cornerstone of adjuvant therapy
for advanced rectal cancer. During the first decade of
the 21st century, preoperative radiochemotherapy with
5-FU became the standard perioperative therapy for
locally-advanced rectal cancer due to its higher efficacy
in reducing local recurrences and improving disease free
survival compared with postoperative radiotherapy, but
with no significant advantage in overall survival [18–20].
But for limitation in preoperative assessment, a relative
number of patients were understaged, and postoperative
radiotherapy was an important complementary. Moreover,
most clinical trial only included rectal adenocarcinoma,
and the therapy strategies for MC referred to adenocarcin-
oma. It has been clearly demonstrated that MC is a
distinct group of tumors which shows different natural
history, biological behavior, different oncogenic and mo-
lecular pathways which may make them respond differ-
ently to chemoradiation compared to adenocarcinoma
[21–23]. However, no current guidelines describe MC as a
clinical factor that should influence the therapeutic
algorithm. In the era of precise medicine and personalized
treatment, it is urgent to know the prognosis value of
postoperative radiotherapy in rectal MC.
For low incidence rate of MC in rectal cancer, it will be
difficult to accumulate an adequate number of patients
treated at a single center. Therefore, we used a large, na-
tionwide, population-based cancer registry, the SEER data-
base, to guarantee power effect for determining the
postoperative radiotherapy value of the MC subtype of
stage II and III rectal cancer. For there has been great ad-
vancements advances in modern radiotherapy in the last
Fig. 1 The flow chart of the study
Table 1 Characteristics of patients included in the study and
comparisons between with and without adjuvant radiotherapy
subgroups
Adjuvant Radiotherapy P value
Total No Yes
Characteristic (n = 574) (n = 326) (%) (n = 248) (%)
Sex 0.409
Male 336 186(57.1) 150(60.5)
Female 238 140(42.9) 98(39.5)
Age <0.001
≤60 185 79(24.2) 106(42.7)
>60 389 247(75.8) 142(57.3)
Race 0.164
White 492 285(87.7) 207(83.5)
Black 46 20(6.2) 26(10.5)
Other 36 21(6.2) 15(6.0)
Pathological grading 0.378
High/Moderate 395 232(71.2) 163(65.7)
Poor/Anaplastic 135 71(21.8) 64(25.8)
Unknown 44 23(7.1) 21(8.5)
Tumor size(cm) 0.043
<5 253 135(41.4) 118(47.6)
≥5 277 171(52.5) 106(42.7)
Unknown 44 20(6.1) 24(9.7)
LNs retrieval 0.107
<12 185 114(35.0) 71(28.6)
≥12 389 212(65.0) 177(71.4)
TNM stage 18(1.6) 5(1.0)
II 239 163(50.0) 76(30.6) <0.001
III 335 163(50.0) 172(69.4)
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decade for rectal cancer [3], we limited the diagnosis from
2004 to 2011 to minimize the confusion. Our study dem-
onstrated that only stage II rectal MC benefit from post-
operative radiotherapy, and postoperative radiotherapy
was an independently prognostic factor in MC rectal
cancer. Considering the toxicity of radiotherapy, postoper-
ative radiotherapy should be recommended with caution
for stage III rectal MC.
To our knowledge, the present study is the largest
and the first study analyzing the prognostic value of
Fig. 2 Survival analysis of rectal MC with postoperative radiotherapy or surgery alone. The 5-year CSSs of patients in postoperative radiotherapy
group and surgery alone group were 74.8 and 70.5%, respectively, of which the difference was not statistically significant (χ2 = 0.560, P = 0.454)
Fig. 3 Subgroup analysis the effect of postoperative radiotherapy on rectal MC. The 5-year CSSs of patients in postoperative radiotherapy group and
surgery alone group in: (a) stage II rectal MC, 93.3% vs. 76.6%, χ2 = 4.654, P = 0.031, (b) stage III rectal MC, 67.5% vs. 64.7%, χ2 = 0.186, P = 0.666
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postoperative radiotherapy for MC in stage II and
stage III rectal cancer patients. Pooled analysis data
from different SEER register centers enabled us to
systemically know the protective effect of postopera-
tive radiotherapy in stage II rectal MC. Although
this is a large population based study, it should be ac-
knowledged that the result should be interpreted in
the light of several limitations. First, there were no
information about radiotherapy dosage and additional
adjuvant chemotherapy, which may cause confusion.
Second, we only selected patients who were patho-
logically diagnosed as stage II and III rectal cancer
and with at least 1 lymph node retrieval to speculate
that they had received radical resection. The quality
of surgery cannot be assessed in this retrospective
study. Third, patients with postoperative radiotherapy
has a higher rate of young patients probably with bet-
ter health and less comorbidities, and therefore, with
a better prognosis, which may cause bias to analysis.
Fourth, the SEER data lacks the information of local
control and relapse free survival, which were the
main benefits for radiotherapy in rectal cancer. How-
ever, there was defined CSS benefit in stage II rectal
MCs who received postoperative radiotherapy, which
was sufficient to support the advantage of postopera-
tive radiotherapy in such subgroup of patients. For
stage III rectal MC, the possible of local control
cannot be converted to CSS advantage.
Conclusion
According to the findings in our study, we suggest that
postoperative radiotherapy should be routinely applied
Table 2 Univariate and multivariate survival analyses on radiation sequence and cancer specific survival for patients with stage II
mucinous rectal cancer
Variable Univariate analysis Multivariate analysis















Tumor size(cm) 0.009 0.014
<5 Reference Reference
≥5 4.142(1.525-11.250) 0.005 3.896(1.428–10.627) 0.008
Unknown 5.720(1.651-19.817) 0.006 5.251(1.493–18.469) 0.010
LNs retrieval 0.770 NI
<12 Reference
≥12 1.122(0.519-2.424)
T Stage 0.040 0.028
T3 Reference Reference
T4 2.487(1.042-5.939) 2.751(1.116–6.780)
Radiation sequence 0.039 0.035
No radiation Reference Reference
After surgery 2.786(1.053-7.371) 0.346(0.129–0.927)
*including other (American Indian/AK Native, Asian/Pacific Islander) and unknown
NI: not included in multivariate survival analysis
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to patients with stage II rectal MC for significantly im-
proved CSS. For stage III patients, considering the losing
of CSS advantage and potential radiotherapy toxicity,
radiotherapy should be recommended with great caution.
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